𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A combination of chemical derivatisation and improved bioinformatic tools optimises protein identification for proteomics

✍ Scribed by Francesco L. Brancia; Amna Butt; Robert J. Beynon; Simon J. Hubbard; Simon J. Gaskell; Stephen G. Oliver


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
637 KB
Volume
22
Category
Article
ISSN
0173-0835

No coin nor oath required. For personal study only.

✦ Synopsis


The identification of individual protein species within an organism's proteome has been optimised by increasing the information produced from mass spectral analysis through the chemical derivatisation of tryptic peptides and the development of new software tools. Peptide fragments are subjected to two forms of derivatisation. First, lysine residues are converted to homoarginine moieties by guanidination. This procedure has two advantages, first, it usually identifies the C-terminal amino acid of the tryptic peptide and also greatly increases the total information content of the mass spectrum by improving the signal response of C-terminal lysine fragments. Second, an Edman-type phenylthiocarbamoyl (PTC) modification is carried out on the N-terminal amino acid. The renders the first peptide bond highly susceptible to cleavage during mass spectrometry (MS) analysis and consequently allows the ready identification of the N-terminal residue. The utility of the procedure has been demonstrated by developing novel bioinformatic tools to exploit the additional mass spectral data in the identification of proteome proteins from the yeast Saccharomyces cerevisiae. With this combination of novel chemistry and bioinformatics, it should be possible to identify unambiguously any yeast protein spot or band from either two-dimensional or one-dimensional electropheretograms.


πŸ“œ SIMILAR VOLUMES


Rapid Identification of a Protein Bindin
✍ Andrew M. Piggott; Peter Karuso πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 561 KB

Dedicated to the memory of Professor Paul J. Scheuer Kahalalide F (KF) is in phase II clinical trials as an anticancer drug against a range of difficult to treat solid tumors including prostate, breast and colon carcinomas, neuroblastomas, chondrosarcomas, and osteosarcomas and has relatively low to

Surface-Plasmon-Resonance-Based Chemical